Journal
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
Volume 59, Issue 3, Pages 179-193Publisher
SPRINGER BASEL AG
DOI: 10.1007/s00005-011-0120-7
Keywords
Myelin; Transplantation; Oligodendrocyte; Development; Pelizaeus-Merzbacher disease; Cell-replacement; Leukodystrophy
Categories
Funding
- California Institute for Regenerative Medicine [NIH K08 NS062744]
- Howard Hughes Medical Institute
Ask authors/readers for more resources
Oligodendrocytes are the primary source of myelin in the adult central nervous system (CNS), and their dysfunction or loss underlies several diseases of both children and adults. Dysmyelinating and demyelinating diseases are thus attractive targets for cell-based strategies since replacement of a single presumably homogeneous cell type has the potential to restore functional levels of myelin. To understand the obstacles that cell-replacement therapy might face, we review oligodendrocyte biology and emphasize aspects of oligodendrocyte development that will need to be recapitulated by exogenously transplanted cells, including migration from the site of transplantation, axon recognition, terminal differentiation, axon wrapping, and myelin production and maintenance. We summarize studies in which different types of myelin-forming cells have been transplanted into the CNS and highlight the continuing challenges regarding the use of cell-based therapies for human white matter disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available